The cost and burden of cancer in the European Union 1995–2014

European Journal of Cancer

Volumn 66, Issue , 2016, Pages 162-170

  Jönsson, Bengt ^a   Hofmarcher, Thomas ^b   Lindgren, Peter ^c   Wilking, Nils ^d  

^a STOCKHOLM SCHOOL OF ECONOMICS   (Sweden)

^b LUND UNIVERSITY   (Sweden)

^c SWEDISH INSTITUTE FOR HEALTH ECONOMICS   (Sweden)

^d KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Cost of cancer drugs; Direct costs; EU; Indirect costs; National expenditures on cancer

Indexed keywords

ANTINEOPLASTIC AGENT;

ARTICLE; CANCER INCIDENCE; CANCER MORTALITY; DRUG COST; EUROPEAN UNION; HEALTH CARE COST; HEALTH CARE SYSTEM; HUMAN; NEOPLASM; PREMATURE MORTALITY; PRIORITY JOURNAL; ADOLESCENT; ADULT; AGED; CHILD; COST; COST OF ILLNESS; ECONOMICS; EPIDEMIOLOGY; EUROPE; MIDDLE AGED; MORTALITY; NEOPLASMS; ORGANIZATION AND MANAGEMENT; STATISTICS AND NUMERICAL DATA; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC AGENTS; CHILD; COST OF ILLNESS; COSTS AND COST ANALYSIS; DRUG COSTS; EFFICIENCY, ORGANIZATIONAL; EUROPE; EUROPEAN UNION; HEALTH EXPENDITURES; HUMANS; MIDDLE AGED; MORTALITY, PREMATURE; NEOPLASMS; YOUNG ADULT;

EID: 84984604188     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2016.06.022     Document Type: Article

References (22)

1. [1] Jönsson B, Hofmarcher T, Lindgren P, Wilking N. Comparator report on patient access to cancer medicines in Europe revisited. IHE Report 2016:4. IHE, Lund, Sweden.
2. [2] Wilking, N., Jönsson, B., A pan-European comparison regarding patient access to cancer drugs. 2005, Karolinska Institutet in collaboration with Stockholm School of Economics, Stockholm.
3. [3] Jönsson, B., Wilking, N., A global comparison regarding patient access to cancer drugs. Ann Oncol 18:Suppl. 3 (2007), iii1–iii77.
4. [4] Eurostat. GDP and main components – current prices [nama_gdp_c] [February 11, 2016]. Available from: http://ec.europa.eu/eurostat/.
5. [5] Eurostat. GDP and main components (output, expenditure and income) [nama_10_gdp] + Main GDP aggregates per capita [nama_10_pc] [January 22, 2016]. Available from: http://ec.europa.eu/eurostat/.
6. [6] World Health Organization. Global health expenditure database [February 12, 2016]. Available from: http://apps.who.int/nha/database.
7. [7] International Agency for Research on Cancer (IARC). WHO cancer mortality database [January 18, 2016]. Available from: http://www-dep.iarc.fr/WHOdb/WHOdb.htm.
8. [8] Eurostat. Structure of earnings survey: annual earnings [earn_ses_annual] [January 29, 2016]. Available from: http://ec.europa.eu/eurostat/.
9. [9] Eurostat. Employment rates by sex, age and citizenship (%) [lfsa_ergan] [January 29, 2016]. Available from: http://ec.europa.eu/eurostat/.
10. [10] Eurostat. HICP (2005 = 100) – annual data (average index and rate of change) [prc_hicp_aind] [January 22, 2016]. Available from: http://ec.europa.eu/eurostat/.
11. [11] Eurostat. Causes of death – deaths by country of residence and occurrence [hlth_cd_aro] [February 1, 2016]. Available from: http://ec.europa.eu/eurostat/.
12. [12] Ferlay, J., Soerjomataram, I., Ervik, M., Dikshit, R., Eser, S., Mathers, C., et al. GLOBOCAN 2012 v1.0, Cancer incidence and mortality Worldwide: IARC CancerBase No. 11 [Internet]. 2013, International Agency for Research on Cancer [February 7, 2016]. Available from: http://globocan.iarc.fr.
13. [13] Bray, F., Sankila, R., Ferlay, J., Parkin, D.M., Estimates of cancer incidence and mortality in Europe in 1995. Eur J Cancer 38:1 (2002), 99–166.
14. [14] World Health Organization. Metrics: Disability-Adjusted Life Year (DALY) [February 7, 2016]. Available from: http://www.who.int/healthinfo/global_burden_disease/metrics_daly/en/.
15. [15] World Health Organization, Global Health Estimates Summary Tables Disease Burden – Estimates for 2000–2012. 2014 [August 11, 2015]. Available from: http://www.who.int/healthinfo/global_burden_disease/estimates/en/index2.html.
16. [16] Hodgson, T.A., Meiners, M.R., Cost-of-illness methodology: a guide to current practices and procedures. Milbank Mem Fund Q Health Soc 60:3 (1982), 429–462.
17. [17] Luengo-Fernandez, R., Leal, J., Gray, A., Sullivan, R., Economic burden of cancer across the European Union: a population-based cost analysis. Lancet Oncol 14:12 (2013), 1165–1174.
18. [18] Federal Statistical Office (Destatis – Statistisches Bundesamt), Krankheitskosten: Deutschland, Jahre, Krankheitsdiagnosen 2002–2008 [Medical Expenses: Germany, years, disease diagnoses 2002–2008] (Table 23631-0001). September 14, 2015 Available from: https://http://www.destatis.de/DE/ZahlenFakten/GesellschaftStaat/Gesundheit/Krankheitskosten/Krankheitskosten.html.
19. [19] Bosanquet, N., Sikora, K., The economics of cancer care in the UK. Lancet Oncol 5:9 (2004), 568–574.
20. [20] Mariotto, A.B., Yabroff, K.R., Shao, Y., Feuer, E.J., Brown, M.L., Projections of the cost of cancer care in the United States: 2010–2020. J Natl Cancer Inst 103:2 (2011), 117–128.
21. [21] Aziz, N.M., Rowland, J.H., Trends and advances in cancer survivorship research: challenge and opportunity. Semin Radiat Oncol 13:3 (2003), 248–266.
22. [22] Siegel, R., DeSantis, C., Virgo, K., Stein, K., Mariotto, A., Smith, T., et al. Cancer treatment and survivorship statistics, 2012. CA Cancer J Clin 62:4 (2012), 220–241.